Soft Tissue Sarcoma Treatment Market Share, Size, Trends, Analysis, Industry Report By Treatment Type, By End User, By Geography, Segments and Forecast, 2014 - 2025

Report Summary

Sarcoma is one type of malignant tumor cancer that grows from tissues such as blood vessels, muscles, nerves, deep skin tissues, and fats. It arises at a body part that supports and protects surrounding the organs. Sarcoma is a life-threatening ailment when cancer has spread to the other body parts. At present, there are approximately 50 different forms of soft tissue sarcoma, including Malignant Mesenchymoma, Adult Fibrosarcoma, Clear Cell Sarcoma, Kaposi Sarcoma, Rhabdomyosarcoma, Angiosarcoma, and Alveolar soft-part sarcoma.

可以用一些诊断分析鉴定软组织肉瘤，例如PET扫描，CT扫描，超声波，活检，X射线成像和MRI。包括物理检查的诊断测试用于诊断软组织肉瘤的阶段，这对于组织治疗方法很重要。根据美国癌症协会的说法，大约12,390名患有软组织肉瘤的新患者均估计在美国诊断为2017年底，据报告约55％的病例被诊断为男性人口的肉瘤。此外，根据在即将到来的年度的软组织Sarcoma，预计5150个美国人的报告预计会死亡。用于治疗软组织肉瘤的少数药物包括多柔比星（Adriamycin），捕获素（Yondelis），Bevacizumab（Avastin），西罗莫司（Supamune），以及孙尼替尼（Sutent）等。

Increasing occurrence of sarcoma cancer demanding proper treatment to boost the market for Soft Tissue Sarcoma Treatment

Increasing number of people suffering from soft tissue sarcoma is anticipated to boost the soft tissue sarcoma treatment market growth. In addition, major factors driving the global market growth include growing research and development infrastructure, targeted drug therapies for oncology treatment along with the enhanced expiration of patents. The rise in spending on healthcare for appropriate patient care and several advanced treatments are other factors bolstering the growth of global market. In addition, increasing focus on adapted medication along with enormous assets for anti-cancer treatment research is expected to reveal new paths for soft tissue sarcoma treatment market during the forecast period.

然而，治疗和药物的高成本以及相关的副作用是可能妨碍市场增长的因素。此外，诊断成本高，包括放射治疗，化疗，严格的政府监管，以及该市场预期的挑战是挑战。

Global Soft Tissue Sarcoma Treatment Market Taxonomy

The Global Soft Tissue Sarcoma Treatment Market is segmented on the basis of treatment, end user, and geography.

On the basis of treatment, market is segmented into

• Chemotherapy
• 有针对性的治疗方法
• Anti-angiogenesis drugs
• 放射治疗
  • External Radiation Therapy
  • External Radiation Therapy

在最终用户的基础上，市场被分段为

• Hospitals
• Diagnostic Centers
• Oncology Centers

Geographically, this market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Asia Pacific region expected to witness dominating growth due to increased spending intended for oncology diagnosis

在地理学的基础上，北美估计占据了软组织肉瘤治疗市场。主要市场份额主要是由于该地区肿瘤学案件的高普及率。根据美国癌症协会，每年在美国诊断出来，超过10,500例软组织肉瘤或2％的癌症。略高于其中的一半是男性。因此，预计急需，要求苛刻的护理和药物，在该地区的软组织Sarcoma治疗市场升高。但是，预计亚太地区在预测期间预计会产生重大增长。增加癌症病例和提高晚期癌症治疗的意识是预期的因素，以提高亚太地区的市场。此外，预计与癌症和相关疾病相关的生育保健支乐动娱乐官网出将在预测期间提高市场增长。

Key players in global Soft Tissue Sarcoma Treatment Market

• Eli Lilly and Company
• Genentech USA
• Pfizer，Inc。
• Johnson & Johnson Services, Inc.
• 葛兰素史克公司
• Bristol-Myers Squibb
• Teva Pharmaceuticals
• Hoffmann-La Roche Ltd
• Celgene Corporation